LFSTHealthcare · Medical Care FacilitiesThe 11 Wall Street analysts covering Lifestance Health Group, Inc. hold a median 12-month price target of $15 — +19.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 94 of 100 as at 14 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Lifestance Health Group, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (99): The shares have been drifting up relative to others.
Value (46): The shares cost a lot relative to the profits and assets behind them.
Size (23): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on LFST, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +19.8% from it.
Of the 20 most recent actions, 10 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 5 Oct 2026 | Keybanc | Maintains | Overweight | $13 → $15 |
| 10 Sept 2026 | Barclays | Maintains | Overweight | — |
| 10 Sept 2026 | Barclays | Maintains | Overweight | $13 → $15 |
| 9 Sept 2026 | Canaccord Genuity | Maintains | Buy | — |
| 9 Sept 2026 | Canaccord Genuity | Maintains | Buy | $13 → $15 |
| 19 Aug 2026 | BTIG | Maintains | Buy | $16 → $18 |
| 19 Aug 2026 | BTIG | Maintains | Buy | — |
| 14 Aug 2026 | JP Morgan | Maintains | Neutral | $9.00 → $13 |
| 14 Aug 2026 | JP Morgan | Maintains | Neutral | — |
| 7 Aug 2026 | BTIG | Maintains | Buy | — |
| 7 Aug 2026 | BTIG | Maintains | Buy | $15 → $16 |
| 24 July 2026 | BTIG | Maintains | Buy | — |
| 24 July 2026 | BTIG | Maintains | Buy | $12 → $15 |
| 21 July 2026 | Canaccord Genuity | Maintains | Buy | — |
| 21 July 2026 | Canaccord Genuity | Maintains | Buy | $11 → $13 |
| 14 July 2026 | Barclays | Maintains | Overweight | — |
| 14 July 2026 | Barclays | Maintains | Overweight | $9.00 → $13 |
| 13 July 2026 | Keybanc | Maintains | Overweight | — |
| 13 July 2026 | Keybanc | Maintains | Overweight | $11 → $13 |
| 5 June 2026 | Goldman Sachs | Initiates | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LFST appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, Lifestance Health Group, Inc. returned +146.0% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 7% of US stocks
Cheaper than 40% of US stocks
Cheaper than 29% of US stocks
Cheaper than 6% of US stocks
Higher than 75% of US stocks
Higher than 98% of US stocks
Higher than 42% of US stocks
Higher than 59% of US stocks
Higher than 56% of US stocks
Higher than 50% of US stocks
Higher than 61% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Lifestance Health Group, Inc. has a market value of $4.8B and an enterprise value of $5.0B.
Revenue in the twelve months to 30 June 2026: $1.6B. The latest quarter grew 26.1% year on year.
Net income over the same four quarters: $50.6M, a 3.2% net margin.
Free cash flow in the twelve months to 30 June 2026: $173.9M.
Trailing P/E: 96.3×; forward P/E: 29.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Lifestance Health Group, Inc. employs 8,542 people — $186K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Lifestance Health Group, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research highlights gains by HF Sinclair, Accenture and FirstCash, citing its research portfolios amid market uncertainty and shifting investor sentiment.
Why it matters — The item does not discuss Lifestance Health Group, so it provides no company-specific information for LFST watchers.
LifeStance Health released a survey finding that nearly half of Americans say fear of an unwanted viral moment keeps them from being themselves in public, and that nearly 3 in 4 Gen Zers say this fear affects their mental health, self-expression and social participation.
Why it matters — The survey highlights growing public awareness of mental-health concerns tied to social media, which could draw attention to the broader behavioral-health space LifeStance operates in.
LifeStance Health's Chief Technology Officer, Vukasin Paunovich, disposed of 42,067 shares for $541,402. The sale represented 17% of the executive's total stake held prior to the filing.
Why it matters — A watcher of LFST would care because a top executive reducing his stake could signal insider sentiment about the company's outlook.
LifeStance Health Group, Inc. presented at the Morgan Stanley 24th Annual Global Healthcare Conference, where its remarks were captured in a transcript published by Seeking Alpha.
Why it matters — A LFST watcher would care because the company used a major investor conference platform to communicate with analysts and shareholders.
Zacks Investment Research published a piece examining whether LifeStance Health Group (LFST) has what it takes to be a top stock pick for momentum investors. The headline characterizes LFST as a great momentum stock.
Why it matters — The article offers LFST watchers an assessment of the company's standing as a momentum pick.
The 11 Wall Street analysts covering Lifestance Health Group, Inc. have a median 12-month price target of $15, with estimates ranging from $12 to $18. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 11 analysts covering Lifestance Health Group, Inc., 9 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Lifestance Health Group, Inc. 94 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, Lifestance Health Group, Inc. ranks 94 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (99 of 100).
No one can know that. What the data says: the median 12-month target from 11 analysts implies +19.8% from the last close, and Ticker Nerd's factor model ranks Lifestance Health Group, Inc. 94 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Lifestance Health Group, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LFST are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $18 over the next 12 months.
Lifestance Health Group, Inc. returned +146.0% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
LifeStance Health Group, Inc. is a U.S.
The most recent item we track (Zacks Investment Research, 12 Oct 2026): "Take the Zacks Approach to Beat the Markets: HF Sinclair, Accenture & FirstCash in Focus". Zacks Investment Research highlights gains by HF Sinclair, Accenture and FirstCash, citing its research portfolios amid market uncertainty and shifting investor sentiment.
LifeStance Health Group, Inc. is a U.S. behavioral health services company that provides outpatient mental healthcare for children, adolescents, adults, and older patients. LifeStance offers psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family, and group therapy. Its care model combines in-person visits at a broad network of centers with virtual appointments through its digital platform, giving patients access to coordinated mental health support across multiple settings. The company serves a wide range of common mental health needs through evidence-based, medically guided services delivered by licensed clinicians. LifeStance Health Group, Inc. focuses on outpatient care and operates as a single mental health services segment, making it a specialized provider within the healthcare market.
CEO Mr. David Patrick Bourdon · 8,542 employees · United States · https://lifestance.com
